BC Week In Review | Nov 9, 2009
Clinical News

Advanced Cancer Therapeutics preclinical data

Researchers at the University of Louisville published in Oncogene that selective inhibition of choline kinase (CHK) expression simultaneously attenuated two cellular signaling pathways required for cancer cell growth and survival - the mitogen activated protein kinase...
BC Week In Review | Jun 8, 2009
Company News

Advanced Cancer Therapeutics, University of Louisville deal

Advanced Cancer received exclusive, worldwide rights from the university's James Graham Brown Cancer Center to develop and commercialize CK37 . The small molecule inhibitor of choline kinase (CHK) is in preclinical testing for cancer. The university...
Items per page:
1 - 2 of 2